Immunogenicity and safety of SARS-CoV-2 recombinant spike protein vaccine in South African people living with and without HIV-1 infection: A phase 2 randomised trial

Authors:

Abstract
No abstract available
Funding Information
  • Novavax Inc

This publication has 22 references indexed in Scilit: